When the application to Health Canada is made it will be from the University of Alberta for the AAGP molecule to join the Edmonton Protocol in the fight against Type 1 Diabetes. Already published in the Journal of Diabetes, this will propel AAGP further in the scientific community. It will also lead people to the owners of the patents and Protokinetix. They will see a molecule that could dramatically lessen the amount of Insulin needed for Type 1. Which so happens to be a 53 BILLION dollar industry. Getting to Phase 1 and 2 trials will get noticed and noticed big time. Biotech and Pharmaceutical companies will take note and will see a very healthy balance sheet of PKTX. ZERO DEBT, cash on hand. Filings up to date. Major insider buying.